B08-Attachment J - Govt Responses - Amendment 0004.xlsx

XLSX spreadsheet 47 KB Posted

Attached to
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
Solicitation number
HT9427-26-R-E020
Issued by
Not on record

About this file

This file is a government responses document to offeror questions related to the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination prototype development solicitation. The document addresses inquiries from potential contractors regarding the solicitation requirements, technical specifications, and evaluation criteria for developing a wound treatment product that combines a physical barrier with infused or impregnated antimicrobial and/or antifungal properties requiring FDA approval or clearance. The Defense Health Agency Contracting Activity (DHACA) issued this solicitation under prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022, with the award to support the Warfighter Protection and Acute Care Project Management Office (WPAC PMO) at Fort Detrick, Maryland. This amendment incorporates the official government responses to clarify solicitation language, technical requirements, contractual terms, and submission expectations for all offerors submitting proposals by the extended deadline of 12:00 p.m. Eastern Time on Friday, November 20, 2026. The responses provide critical guidance on proposal preparation, evaluation methodology, compliance requirements including Cybersecurity Maturity Model Certification (CMMC) Level I self-assessment, and clarification on the statement of work template and draft agreement terms and conditions for the single award anticipated under this procurement.

View the file

Other files

File Type Posted
RPP for BWI-PT-Barrier (pOTA) - Amendment 0005.pdf PDF
B08 -Attachment K - CMMC Level 1 self-assessment instructions (INFORMATION ONLY).pdf PDF
B08-Attachment H-SOW-Amendment 0004.pdf PDF
B08-Attachment A-SOO-Amendment 0004.pdf PDF
B08-RPP for BWI-PT-Barrier (pOTA) - Amendment 0004.pdf PDF
B08-Attachment E-Draft Agreement Terms Conditions-Amendment 0004.pdf PDF
B08-HT9427-26-R-E020-Amendment 0003-RPP for BWI-PT-Barrier (pOTA).pdf PDF
HT9427-26-R-E020-Amendment 0002-RPP for BWI-PT-Barrier (pOTA).pdf PDF
Attachment I1 - Technology Readiness Level (TRL) for drug and biologics (REFERENCE ONLY).pdf PDF
Attachment I2-Technology Readiness Level (TRL) for diagnostics and devices (REFERENCE ONLY).pdf PDF
HT9427-26-R-E020-RPP for BWI-PT-Barrier (pOTA).pdf PDF
Attachment D2 - FDA Form 1571 Instructions (REFERENCE ONLY).pdf PDF
Attachment G2 - Firm Fixed Price Sheet Template.xlsx XLSX spreadsheet
Attachment J - Offeror question form.xlsx XLSX spreadsheet
Attachment D1 - FDA Form 1571.pdf PDF
Attachment B - Contract Data Requirements List (CDRL).pdf PDF
Attachment A - Statement of Objectives (SOO).pdf PDF
Attachment F - Warranties and Representatives.docx DOCX document
Attachment C - Data Item Description (DID) DI-TCSP-82040 (REFERENCE ONLY).pdf PDF
Attachment E - Draft Agreement Terms and Conditions.pdf PDF
Attachment G1 - Cost Sheet Template.xlsx XLSX spreadsheet
Attachment H - Statement of Work Template (see Section 11).docx DOCX document
Show all 22

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Attachment J - Q&A

HT9427-26-R-E020 Q&A for Amendment 0004
Question NumberDocumentSectionSub SectionOfferor Question(s)Government Response
1Request for Project Proposal (RPP)Section 1.1 "Request for Project Proposal"N/AThe Barrier Combination product is defined as a barrier that is "infused or impregnated" with antimicrobial and/or antifungal properties "released from the barrier." Would a barrier whose antimicrobial activity is intrinsic to the barrier material itself, and whose active moiety is liberated as the barrier biodegrades in situ rather than eluted from a separately incorporated agent, satisfy this definition?Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth . The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A - SOO has been updated.
2Request for Project Proposal (RPP)Section 1.1 "Request for Project Proposal"N/AMay the barrier component be a product that already holds FDA clearance for a different indication, with the prototype effort directed at establishing the antimicrobial function and obtaining approval or clearance for the combination indication?Yes, initial clearance for a partial indication may be achieved early after award followed by an FDA submission for full indication by end of period of performance as long as Performance Attributes (i.e. SOO, Section 4.0) are achieved in final form configuration for full indication submission to FDA.
3Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Objective 1Is the Government open to a proposal in which the specific antimicrobial constituent is down selected during Objective 1 from a defined candidate set, rather than fixed at the time of proposal submission?Per the RPP, only 1 award will be made and no down selection will be conducted after award . The timeline for achieving FDA clearance/approval will not allow for a down-selection to occur.
4Attachment A, Statement of ObjectivesSection 1.0 "Purpose"Regulatory SponsorThe Statement of Objectives states it is the Government preference that the Prime Performer serve as the Regulatory Sponsor. May the antimicrobial constituent be supplied by a subawardee or teaming partner that holds the associated regulatory filings, with the Prime Performer serving as Regulatory Sponsor of the combination product?Yes.
5Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Required Attributes, Barrier IntegrityThe required attribute states the barrier "must remain physically intact on the wound for a minimum of 24 hours." Is there a defined test method or acceptance criterion for barrier integrity?The Government will rely on FDA testing criteria to support FDA clearance/approval.
6Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Required Attributes, Barrier IntegrityDoes "intact" refer to the barrier alone, or is retention of the barrier beneath a secondary dressing acceptable?Yes, a two-part product would be considered.
7Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Required Attributes, Barrier IntegrityWould a single reapplication of the barrier within the 24 hour period disqualify a candidate?Products with fewer changes over the 24 hour time period are more advantangeous to the Government.
8Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Required Attributes, Antimicrobial EfficacyThe required attribute states the product must "at minimum, prevent bacterial infection." Is there a required pathogen panel, and is there a required log reduction or other quantitative acceptance criterion?Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth . The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A - SOO has been updated.
9Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Required Attributes, Antimicrobial EfficacyMust antimicrobial efficacy be demonstrated in vivo, or are in vitro data supported by an animal model sufficient?The Government will rely on FDA testing criteria to support FDA clearance/approval.
10Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Recommended Attributes, Wound CoverageThe recommended attribute states the product should cover and treat wounds covering a minimum of 15 percent of total body surface area. Is this to be achieved from a single unit as carried in the Individual First Aid Kit, or cumulatively across multiple units?15% coverage could be achieved through multiple applications; ideally aiming for a single unit to have enough to achieve the required minimum coverage using the IFAK (Individual First Aid Kit) kit.
11Attachment A, Statement of ObjectivesSection 4.0 "Objectives"Recommended Attributes, CompatibilityThe recommended attribute states the product "does not interfere with, or degrade the performance of standard hemostatic agents." Which hemostatic agents does the Government consider standard for this purpose, and what test method will be used to evaluate this attribute?Combat gauze (QuikClot) has an imbedded hemostatic agent that may be in contact with any proposed products.
12Attachment A, Statement of ObjectivesSection 3.0 "Scope of Effort"N/AIs a bioabsorbable barrier that requires no physical removal acceptable under this requirement?A bioabsorable barrier may be considered as long as it meets the requirements of preventing wound infections by inhibiting growth and is within toxicity limitations for human use per FDA. It is advantagous to the Government if the product can inhibit growth of "bacterial" AND "fungal" organisms. Minimum requirement is inhibiting growth of "bacteria".
13Request for Project Proposal (RPP)Section 2.6 "Preliminary Screening & Eligibility"Attachment D1, FDA Form 1571Attachment D1 is FDA Form 1571, an Investigational New Drug form. For a device led combination product pursuing an Investigational Device Exemption and a 510(k), De Novo or Premarket Approval, does the Sponsor confirmation requirement apply in the same manner, and what should be submitted in place of Form 1571? If the FDA lead center has not yet been designated at the time of proposal submission, what will satisfy this requirement?Whatever FDA pathway is applicable to the Offerer's proposed product, the Offeror shall serve as the regulatory sponsor. The Government has not made any juridictional determination for a barrier combination product of this type.
14Attachment A, Statement of ObjectivesSection 3.0 "Scope of Effort"N/AThe Statement of Objectives anticipates that data will support a future New Drug Application or Premarket Approval Application. Is a 510(k) or De Novo pathway acceptable where supported by the Offeror regulatory strategy, or does the Government require a PMA or NDA pathway?Whatever FDA pathway is applicable to the Offeror's proposed product will be accepted. The Government has not made any juridictional determination for a barrier combination product of this type.
15Attachment A, Statement of ObjectivesSection 9.0 "Constraints"Good Laboratory PracticeWill non clinical animal data generated under Good Laboratory Practice at test facilities outside the United States be accepted in support of Objective 1, and will such data be evaluated equally with data generated at United States facilities?The Government will rely on FDA testing criteria to support FDA clearance/approval.
16Request for Project Proposal (RPP)Section 2.1 "Award Type"N/AFirm Fixed Price is stated as the Government preference. Given the cost uncertainty inherent in clinical execution under Objective 2, would the Government consider a hybrid structure, for example Firm Fixed Price for Objective 1 and cost plus fixed fee for Objective 2?Yes.
17Request for Project Proposal (RPP)Section 2.3 "Frequency of funds obligated"N/AIs there a target price range or funding ceiling for this effort, and what is the anticipated incremental funding profile by objective?The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
18Request for Project Proposal (RPP)Section 2.6 "Preliminary Screening & Eligibility"Eligibility conditions (A), (B), (C)Under 10 U.S.C. 4022, cost sharing is not required where the Offeror is a nontraditional defense contractor or small business. Please confirm that no cost share is expected from such an Offeror and that the presence or absence of cost share will not be evaluated.Per the RPP, Section 1.3, if the Offeror does NOT meet the defiintion of a non-traditional defense contractor or small business participating to a “significant extent”, then 1/3 of the total cost of the prototype shall be paid by parties other then the Federal Government. Cost sharing shall be proposed if required per the above.
19Attachment A, Statement of ObjectivesSection 1.0 "Purpose"Follow on productionThe Statement of Objectives states the Government intends to assess whether the prototype is successful for a separate follow on production acquisition, and defines success by reference to key technical goals and success metrics incorporated into the pOTA. How and when will those key technical goals and success metrics be established, and will they be negotiated with the Performer prior to award?Per Attachment A - SOO, Section 1.0, establishes the success of the prototype and will be at the completion of Obj 3. The "success" is a determination of the government and considers, but is not limited to, the objectives and the RECOMMENDED and REQUIRED attributes achieved. If a production requirement is decided, it will be a separate award.
20Request for Project Proposal (RPP)Section 2.5 "Intellectual Property"Agreement Articles 7, 8 and 9Will the Government seek license rights to Offeror background intellectual property, or to data developed at private expense prior to award, including data supporting an existing FDA clearance?Please refer to RPP Section 2.5, which references Attachment E - Draft Agreement Terms & Condition. Attachment E - DRAFT Agreement has been updated.
21Request for Project Proposal (RPP)Section 3.4 "Volume II: Management"Subcontractor Management PlanAre there constraints on including a Department of Defense academic institution as a collaborator or subawardee, and what contractual instrument would the Government expect in that case?No constraints on using a DoD academic institution as a collaborator. The Govt. would need to know whom the government collaborator is and the services they would be providing in association with this requirement and ensure there is no duplication of effort and/or conflict of interest. There may be a variety of ways to approach such a situation; one common approach is to use a CRADA. The Govt. reserves the right to require the funds to be directly transffered from the Govt. to the DoW academic institution rather than letting the funds pass through the awardee.
22Request for Project Proposal (RPP)Section 6 "Attachments"Attachment EAttachment E, Draft Agreement Terms and Conditions, is annotated "RETURN RED-LINED COPY" but does not appear in the Proposal Organization Table at Section 3.2. Is the red lined Draft Agreement due with the proposal on 23 October 2026, or only upon selection?No, a red-lined copy of the Agreement is NOT due with the proposal. Section 3.5 of the RPP states, "The DRAFT agreement is being provided for situational awareness. The Government will provide a tailored DRAFT Agreement once a Performer is selected and the selected Performer will have an opportunity to negotiate terms and conditions with the Government."
23Request for Project Proposal (RPP)Section 3.2 "Organization of Proposal"Proposal Organization TableThe Proposal Organization Table lists the Volume I Technical Approach page limit as "20 ages." Please confirm the limit is 20 pages. Please also confirm that Attachment H Statement of Work and the Integrated Master Schedule are excluded from all volume page limits.As outlined in the Proposal Organization Table under Volume I, the SOW has no page limit. The Integrated Master Schedule (IMS) is part of Volumne II Management Approach, which is subject to 20 page limit. RPP "Proposal Organizational Chart" has been updated to reflect 20 pages."
24Attachment A, Statement of ObjectivesSection 3.0 "Scope of Effort"Technology Readiness LevelThe Statement of Objectives requires TRL 7 at the time of submission to FDA, and the solicitation provides Attachment I1 for drugs and biologics and Attachment I2 for diagnostics and devices. For a combination product, which Technology Readiness Level scale will the Government apply in evaluating the proposal and in assessing prototype completion?A potential solution could be a "drug" led device combination product and therefore, will have to follow the more stringent FDA requirements of a biologic. Thus, the "drugs and biologics" TRL would be more applicable than the "device" TRL alone.
25Attachment A - Statement of Objectives (SOO)Section 1.0 "Purpose"; Section 3.0 "Scope of Effort"N/AThe SOO states that data are anticipated to support a future NDA or PMA. Will the Government accept a barrier combination product that is regulated as a device (primary mode of action is the barrier) with a 510(k) pathway, where the Offeror has already completed an FDA Pre-Submission?Whatever FDA pathway is applicable to the Offorer's proposed product is what should be proposed.
26Attachment A - Statement of Objectives (SOO)Section 4.0 "Objectives"Objectives 1 and 2If FDA does not require an IND, IDE, or pre-market clinical trial for the Offeror's 510(k) submission, and clearance may be obtained early in the period of performance, how should Objectives 1 and 2 be structured? Would the Government accept a clinical study that supports a battlefield-relevant or expanded indication (e.g., traumatic or contaminated wounds) in place of a pivotal pre-market trial, and a period of performance shorter than 54 months?Product must be able to achieve FDA clearance/approval; pathway to get there will be determined by the FDA. Attachment A -SOO has been updated.
27Request for Project Proposal (RPP)Section 2.6 "Preliminary Screening & Eligibility"; Section 3.5Attachment D1 - FDA Form 1571Form FDA 1571 applies to an IND. For a 510(k) device that does not require an IND, what written FDA sponsor confirmation will satisfy the preliminary screening requirement (e.g., a signed sponsor commitment letter referencing the Offeror's FDA Q-Submission number)?Whatever FDA pathway is applicable to the Offerer's proposed product will be accepted. The Government has not made any juridictional determination for a barrier combination product of this type.
28Request for Project Proposal (RPP)Section 4.3 "Evaluation Factors for Award"; Section 2.3N/ASection 4.3 does not list specific evaluation factors. Please identify the evaluation factors, their relative importance, and the basis for award. Can the Government also share an anticipated funding range or budget ceiling for this effort?The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
29Attachment E - Draft Agreement Terms and ConditionsArticle 6 "Payment"N/AFor a Firm Fixed Price milestone-based agreement, may the Offeror propose an initial milestone payable within 30 to 60 days of award (e.g., kick-off, spend plan, business plan, and finalized regulatory and quality plans)?All proposed pricing shall be proposed at time of proposal submission. There is no prohibition on vendor milestone structure, as long as it conforms with RPP instructions.
30Request for Project Proposal (RPP)Section 1.1 "Request for Project Proposal (RPP)"N/ADoes the Barrier Combination definition require the antimicrobial component to be a conventional antibiotic or antifungal drug? Or would a barrier that releases a non-antibiotic antimicrobial agent from the barrier material also qualify?Barrier combination does not have to include a conventional antibiotic/antifungal; however, it must at minimum, inhibit growth of bacterial organisms. It is advantagous to the Government if the product can inhibit growth of "bacterial" AND "fungal" organisms. Attachment A -SOO has been updated.
31Attachment A - Statement of Objectives (SOO)Section 1.0 "Purpose" and Section 4.0 "Objectives"Objective 2Section 1.0 states that data are anticipated to support an NDA or PMA, and Objective 2 requires clinical studies. Would the Government accept a regulatory strategy based on a 510(k) or De Novo device pathway? If FDA does not require clinical data for clearance of the proposed indication, may the Offeror propose clinical work scaled to what FDA requires?Whatever FDA pathway is applicable to the Offerer's proposed product will be accepted. The Government has not made any juridictional determination for a barrier combination product of this type.
32Request for Project Proposal (RPP)Section 2.6 "Preliminary Screening & Eligibility" and Section 3.5Attachment D - FDA Form 1571Form FDA 1571 applies to an IND under 21 CFR 312. If the proposed product is regulated as a device and proceeds under an IDE (21 CFR 812), or without an IDE, what written sponsor confirmation will satisfy the Section 2.6 screening requirement in place of Form FDA 1571?Whatever FDA pathway is applicable to the Offerer's proposed product, the Offerer shall serve as the regulatory sponsor. The Government has not made any juridictional determination for a barrier combination product of this type.
33Request for Project Proposal (RPP)Section 1.3 "Inclusion of Nontraditional Defense Contractors or Nonprofit Research Institutions"NOTEIf the Offeror is a small business concern participating to a significant extent in the prototype project, please confirm that the eligibility requirement of Section 1.3 is met and that no cost share under condition (C) is required.Correct. Per the RPP, Section 1.3, if the Offeror does NOT meet the defiintion of a non-traditional defense contractor or small business participating to a “significant extent”, then 1/3 of the total cost of the prototype shall be paid by parties other then the Federal Government.
34Request for Project Proposal (RPP)Section 2.1 "Award Type"N/ACan the Government share an anticipated funding range or ceiling for the 54-month effort?The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
35Request for Project Proposal (RPP)Section 5 "Proposal Submission"N/AWill the Government hold a pre-proposal conference or allow brief pre-proposal discussions with Offerors before the proposal due date?A pre-proposal conference will NOT be held. If additional clairifications are needed, the government will reach out to the individual Offeror.
36Request for Project Proposal (RPP); Attachment A - Statement of Objectives (SOO)RPP 1.1; SOO 4.0Barrier Combination definition; required Barrier Integrity attributeAre liquid-applied wound dressings with hydrogel properties eligible when the proposed work will demonstrate physical barrier integrity for at least 24 hours and antimicrobial activity released from that barrier? Are there prescribed test methods or acceptance criteria?A liquid-applied dressing may be considered as long as it, at minimum, inhibit growth of bacterial organisms. It must meet the requirements of wound protection from additional contamination and is within toxicity limitations for human use per FDA and relying on the FDA prescibed testing criteria. It is advantagous to the Government if the product can inhibit growth of "bacterial" AND "fungal" organisms. Attachment A -SOO has been updated.
37Attachment A - Statement of Objectives (SOO)3.0; 4.0Scope of Effort; Objectives 1 and 2May an existing FDA-cleared wound dressing be proposed for further development and validation for the battlefield infection-prevention indication? Please clarify the expected regulatory deliverables for a device pathway.The timeline for achieving FDA clearance/approval that meets the required performance attributes relying on the FDA testing criteria may be a limiting factor. Attachment A -SOO has been updated.
38Request for Project Proposal (RPP); Attachment A - Statement of Objectives (SOO)RPP 2.6 and 3.5; SOO 1.0FDA sponsorship; Form FDA 1571The RPP requires the offeror to serve as FDA sponsor and submit Form FDA 1571, while the SOO describes prime-performer sponsorship as a preference. May the manufacturer serve as regulatory sponsor with a U.S. commercial partner as prime? What documentation applies to an IDE/device pathway?Whatever FDA pathway is applicable to the Offerer's proposed product, the Offerer shall serve as the regulatory sponsor. The Government has not made any juridictional determination for a barrier combination product of this type.
39Request for Project Proposal (RPP); Attachment A - Statement of Objectives (SOO)RPP 3.4; SOO 6.0Foreign collaborators; LocationPlease clarify permissible participation by an Israeli manufacturer, including use of existing Israeli clinical or battlefield data and Ukrainian study data, given the requirement for work to be performed within the United States.All data would be considered as long as it is appropriately sourced and meets FDA standards.
40Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 1Is it permissible for the proposed solution to require a commercially and readily available external wrap or secondary dressing to secure the barrier or treatment during patient movement and other operational activities?Yes it is acceptable.
41Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 1Is the barrier component of the proposed solution required to act as a barrier to external moisture?At minimum, the product must inhibit growth of bacterial organisms. It should provide wound protection from additional contamination at the point of injury such as external contaminants (such as moisture) from entering the wound that could potentially result in an infection. It shall NOT act as a "green-house" or "incubator" to any contaminants within the wound as a result of the injury that would result in infection. It is advantagous to the Government if the product can inhibit growth of "bacterial" AND "fungal" organisms. Attachment A -SOO has been updated.
42RPPSection 2 "Requirement Overview"2.2 Period of PerformanceWhen is the anticipated start date for the Period of Performance (PoP), and is there flexibility in establishing the start date?The estimated start timeframe is FY27, 2nd quarter or later.
43RPPSection 2 "Requirement Overview"2.3 Frequency of Funds ObligatedIs there a cap or approximation for the award amount?The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
44Attachment A - Statement of Objectives (SOO)Section 3 "Scope of Effort"N/ADoes the RPP permit the antimicrobial component of the barrier to be incorporated during application, rather than being directly incorporated into the barrier during manufacturing? For example: a prototype kit that is comprised of a powder that is hydrated with an antimicrobial solution at the time of application. Upon hydration with the antimicrobial solution, the powder transforms into an extended wear barrier with infused antimicrobial properties over a sustained period.A two part product would be considered.
45Attachment A - Statement of Objectives (SOO)Section 3 "Scope of Effort"N/ADoes the combination wound treatment need to consist entirely of FDA-approved products? If not, what regulatory status or level of development would be acceptable for the individual components of the combination treatment? Is there a starting TRL level that is preferred?No the product does not have to be entirely FDA approved products. Attachment A - SOO, Sectin 1.0 states, "Technologies starting at a Technology Readiness Level (TRL) 5 or higher are preferred to achieve this goal." The end-state is an FDA cleared/approved products by the end of the period of performance. Attachment A- SOO has been updated.
46Attachment A - Statement of Objectives (SOO)Section 3 "Scope of Effort"N/AAre products with an existing FDA clearance eligible for use in the barrier dressing if development is required to add an antimicrobial component and/or expand the indication?The timeline for achieving FDA clearance/approval that meets the required performance attributes relying on the FDA testing criteria may be a limiting factor.
47Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 1Are Good Laboratory Practice (GLP) studies required for Objective 1 studies?Per Attachment 1 - SOO, Section 9, "Per FDA guidelines, the Performer shall ensure that Good Laboratory Practice (GLP) recommendations are followed for pivotal animal studies.The studies and product development must be compliant with 21 CFR Part 58 and Part 11 and follow FDA’s various guides for industry, as applicable."
48Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objectives 1 and 2Does the antimicrobial barrier need to protect against a specific type/species of microbes? Combining FDA approved products may simplify and expedite the regulatory process, but those products may not be effective on MDR wounds. Most newer antimicrobial products that target MDR species are not approved by FDA.Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth . The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A -SOO has been updated.
49Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objectives 1 and 2Are preclinican and clinical studies expected to evaluate infection prevention, treatment or safety of application of an antimicrobial barrier? Different claims will change the FDA pathway being followed and, accordingly, will impact the type of required studies, sample sizes, budgets and timelines.The FDA will make the determination on which regulatory pathway is acceptable.
50Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 2What phase(s) of clinical studies are required to complete Objective 2? If FDA feedback and the proposed regulatory strategy require studies beyond Phase I safety studies, would it be possible to extend the duration and/or budget allocated to Objective 2?All clinical studies must meet FDA Regulation/Standards (for submission to achieve clearance/approval) and must reviewed/approved by Office of Human Research Oversight (OHRO) & Animal Care and Use Review Office (ACURO) PRIOR TO execution. Scope of work is for completion within 48 months (not to exceed 52 months).
51Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 2Are international clinical sites allowed?Yes but must meet US FDA Regulation/Standards (for submission to achieve clearance/approval) and must reviewed/approved by Office of Human Research Oversight (OHRO) & Animal Care and Use Review Office (ACURO) PRIOR TO execution.
52Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"N/AWould it be possible to introduce a new product during Objective 2? For example, our group has already developed a combinatin dressing with multiple antibiotics under a separate SBIR-funded effort which has shown positive results in the porcine studies. However the FDA conversations to determine the product approval pathway and what clinical studies will be requried are currently anticipated to take place in quarter 1 of CY2026. We are considering testing certain additional antimicrobial /antifungal products in Objective 1 while the FDA covnersations are completed and then selecting the best option for advancement to approval in Objective 2.Per the RPP, only 1 award will be made and no down selection will be conducted after award . The timeline for achieving FDA clearance/approval will not allow for a down-selection to occur.
53Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 3Does FDA clearance/approval have to be obtained during the period of performance, or is submission of the applicable FDA marketing application sufficient if the FDA review extends beyond the six months for Objective 3 due to unanticipated study requirements from the FDA?Per Attachment 1 - SOO, Section 3.0 " FDA approval/clearance MUST achieved during the period of performance." Attachment A -SOO has been updated.
54Attachment A - Statement of Objectives (SOO)Section 4 "Objectives"Objective 3Should the final FDA-cleared or approved indication specifically reference battlefield or combat wounds, or will evidence from civilian wound populations support the intended military use? Clincial studies are harder to execute in a military / combat environment.Yes civilian wound studies are acceptable.
55Request for Project Proposal (RPP)N/AN/ANo detail appears to be provided relating to the Level of Funding available under this award. Is that information available or will this be proposal specific?The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
56N/AN/AN/AWe found the format for each volume in the announcement - can you please clarify the page margins to be used for each volume (Technical/Management/Administrative)?Page margins are 1 inch. The RPP has been updated to reflect this.
57Attachment A — Statement of Objectives (SOO)Section 1.0 "Purpose"; Section 3.0 "Scope of Effort"Antimicrobial mechanismSection 1.0 describes antibacterial and/or antifungal activity "released from the barrier," and Section 3.0 requires a barrier component "infused or impregnated with antimicrobial properties." Please confirm whether the Government requires an antimicrobial agent that is released from the barrier into the wound site to act on organisms in the wound, or whether a material that is itself resistant to bacterial and fungal colonization — without release of an active into the wound — would also satisfy the requirement.Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth. The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A -SOO has been updated.
58Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", REQUIRED attributes tableAntimicrobial EfficacyThe REQUIRED attributes table states "At minimum, prevent bacterial infection," while the RECOMMENDED attributes table states "Desired to prevent and treat bacterial and fungal infections." Please confirm whether the required indication is prevention only, or whether treatment of established infection is also required. Prevention and treatment are distinct indications with different clinical endpoints, trial populations and sample sizes, and the answer materially affects the proposed clinical development plan.Per the SOO, Section 4.0 "REQUIRED," the Government's MINIMUM REQUIREMENT is prevention of "bacterial" infection; it is advantagous to the Government if the product can prevent "bacterial" AND "fungal" infections. The antimicrobial attributes shall meet FDA requirements for prevention of bacterial infections. Attachment A -SOO has been updated.
59Attachment A — Statement of Objectives (SOO)Section 2.0 "Background"; Section 4.0 REQUIRED attributes tableBacterial spectrumIs the Government seeking broad-spectrum antibacterial coverage, or coverage against a specific panel of organisms? If a defined panel exists, please provide the organism list or a reference to the applicable Joint Trauma System or USAMRDC source document. Section 2.0 identifies drug-resistant organisms as a priority; please confirm whether efficacy against specific drug-resistant isolates (for example MRSA, multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa) is required, recommended, or will be scored.Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth. The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A -SOO has been updated.
60Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tableAntifungal requirementAntifungal activity appears in the RECOMMENDED attributes table but not in the REQUIRED table. Please confirm whether antifungal activity is required for award, and whether its inclusion will be evaluated or scored. If specific fungal species are of concern (for example Candida species, Aspergillus species, or Mucorales associated with combat-related invasive fungal wound infection), please identify them, and confirm whether yeast and filamentous fungi are both in scope.Per the SOO, Section 4.0 "REQUIRED,"the Government's MINIMUM REQUIREMENT is to provide protection from additional contamination at the point of injury and inhibit growth of "bacteria"; it is advantagous to the Goverment if the product can inhibit "bacterial" AND "fungal" growth. The antimicrobial attributes shall meet FDA requirements for prevention of bacterial and/or fungal infections. Attachment A -SOO has been updated.
61Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tableColor, visual and infrared signatureIs there a color, shade or signature requirement for the material that covers the wound? Specifically, please confirm whether the covering material must meet any near-infrared or infrared reflectance, low-visibility or camouflage signature requirement applicable to items carried or worn in a tactical environment, and whether a high-visibility or light-colored material presents a concern for a casualty in a field setting. Please also confirm whether any color is required or prohibited for product identification or triage purposes.No.
62Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tablePackaging / sterilityThe RECOMMENDED attributes table requires packaging that "maintains sterilization prior to opening." Please confirm whether the Government requires the wound-contact article itself to be terminally sterilized and labeled sterile, or whether a non-sterile article meeting compendial microbial limits in a sealed, waterproof package would be acceptable. This determines whether a terminal sterilization validation program is required and materially affects cost and schedule.Product components that come into direct contact with the wound must be sterile.
63Attachment A — Statement of Objectives (SOO); Attachment E — Draft Agreement Terms and ConditionsSOO Section 5.0 "Period of Performance"; Draft Agreement period of performancePeriod of performance conflictSOO Section 5.0 states an estimated period of performance of 48 months (Objective 1: 24 months; Objective 2: 24 months; Objective 3: 6 months). Please confirm the period of performance the Government intends to award, and identify any provision of the draft agreement terms that would establish a different period. SOO Section 3.0 requires that the FDA submission be made before the end of the period of performance; a shorter period would require the submission milestone and the clinical development plan to be re-phased accordingly.The estimated start timeframe is FY27, 2nd quarter or later. The Agreement terms & conditions will be negotiated with the successful offeror. The total scope of work is completion within 48 months, but no longer than 54 months (with the last 6 months allowing for FDA review of submission).
64Request for Project Proposal (RPP)Funding / anticipated award valueN/APlease confirm the anticipated total award value and whether any stated funding range is expressed per year or across the full period of performance. Please also confirm whether the Government will consider proposals above or below any stated range where the proposed technical approach justifies it.The Offeror shall submit pricing commensurate with the requirements set forth in the Request for Project Proposal.
65Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tableWound coverageThe RECOMMENDED attributes table specifies coverage of a minimum of 15% of total body surface area. Please confirm whether that coverage must be achieved by a single article or may be achieved by multiple articles supplied together as one kit, and whether the size and weight attributes (IFAK fit; under 8 ounces) apply to the individual article or to the complete kit.15% coverage could be achieved through multiple applications; idealy aiming for a single unit to have enough to achieve the required minimum coverage using the Individual First Aid Kit (IFAK).
66Attachment A — Statement of Objectives (SOO)Section 1.0 "Purpose"; Section 3.0 "Scope of Effort"Regulatory pathwaySection 1.0 anticipates data supporting a future New Drug Application (NDA) or Premarket Approval Application (PMA). Please confirm whether the Government is agnostic as to the FDA center of jurisdiction and the submission type, provided the product is approved or cleared and available through the DLA e-catalog, or whether a particular pathway is preferred or required. For drug-led products, please specifically confirm whether an NDA submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, relying in part on FDA's prior findings for previously approved active ingredients and on published literature, satisfies the requirement, or whether a full NDA under section 505(b)(1) is expected. For device-led products, please confirm whether a 510(k) or De Novo pathway is acceptable.The regulatory pathway will be determined by the FDA based on product attributes and indication for use.
67Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", Objective 2; Section 9.0 "Constraints"Clinical study populationObjective 2 requires clinical studies demonstrating safety and efficacy in humans for an adult indication. Please confirm whether the Government expects those studies to be conducted in the general U.S. civilian population at commercial clinical sites, in a military population at Military Treatment Facilities, or in a combination of both. If studies in a military population are expected or preferred, please confirm the applicable additional requirements, including those arising under 10 U.S.C. 980 and DoDI 3216.02 and USAMRDC Office of Human and Animal Research Oversight review, and the anticipated timeline for that review. Because site population, oversight requirements and review timelines are major drivers of clinical cost and schedule, please confirm the basis on which offerors should price Objective 2, and whether proposals priced on a civilian-site basis will be evaluated as fully responsive.All clinical studies must meet US FDA Regulation/Standards (for submission to achieve clearance/approval) and must reviewed/approved by Office of Human Research Oversight (OHRO) & Animal Care and Use Review Office (ACURO) PRIOR TO execution are to be included in the proposal for submission to achieve clearance/approval. Civilian wound studies (non-combat) are acceptable.
68Attachment A — Statement of Objectives (SOO)Section 8.0 "Government Furnished Property"; Section 4.0 Objective 2Government-furnished clinical resourcesPlease confirm whether the Government intends to furnish any clinical resources for Objective 2 — for example access to Military Treatment Facilities, investigators, Service Member subjects, laboratory services, or regulatory or institutional review support — or whether the Performer should price the full cost of clinical site identification, contracting, conduct and monitoring. If Government resources are available, please confirm whether their cost is Government-furnished or must be carried in the Performer’s proposed price.No.
69Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", REQUIRED attributes tableShelf-life evidenceThe REQUIRED attributes table specifies a minimum 12-month shelf life. Please confirm whether the Government expects real-time stability data covering the full 12 months to be available at FDA submission, or whether a shelf-life claim supported by accelerated data, with a real-time stability program ongoing at the time of submission, would satisfy the requirement.The Government will rely on FDA testing criteria to support FDA clearance/approval that support product indication for use.
70Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tableHemostatic agent compatibilityThe RECOMMENDED attributes table states that the product should not interfere with, or degrade the performance of, standard hemostatic agents or subsequent wound care treatments. Please identify the specific hemostatic agents and wound care products against which the Government expects compatibility to be demonstrated (for example, Combat Gauze or other agents currently fielded under TCCC guidelines), and confirm whether compatibility testing is required or will be scored.Combat gauze (QuikClot) has an imbedded hemostatic agent that may be in contact with any proposed products.
71Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", REQUIRED attributes tablePerformance exceeding minimum requirementsThe REQUIRED attributes table specifies a minimum 12-month shelf life and a minimum 24-hour period during which the barrier remains intact on the wound. Please confirm whether performance exceeding these minimums, for example a shelf life of 24 months or longer, or barrier integrity beyond 24 hours to support prolonged field care, will be evaluated as a strength or otherwise considered in the technical evaluation. Please also confirm whether any target values for extended shelf life or wear time exist that offerors should address.The product minimum performance specifications are in Attachment A - SOO, Section 4.0. Attachment A -SOO has been updated.
72Request for Project Proposal (RPP); Attachment E — Draft Agreement Terms and ConditionsAgreement terms; Defense Priorities and Allocations System (DPAS)DPAS priority ratingPlease confirm whether the resulting Other Transaction Agreement will be a DPAS rated order under 15 CFR Part 700 and, if so, whether it will carry a DO or DX priority rating and the applicable program identification symbol. If the prototype agreement will be unrated, please confirm whether the Government anticipates that a follow-on production award would be rated. Offerors with sole-source or limited-capacity suppliers for drug substance manufacturing, CDMO services and terminal sterilization require this information to plan supplier scheduling and to determine whether the rating may be extended to subcontracts.The government is open to rating the OT under DPAS. If we do, it will likely only be a DO rating, not a DX rating.
73Attachment A — Statement of Objectives (SOO)Section 4.0 "Objectives", RECOMMENDED attributes tableAnatomical coverage prioritiesThe RECOMMENDED attributes table specifies coverage of a minimum of 15% of total body surface area but does not identify anatomical regions. Please confirm whether the Government considers any anatomical regions primary for coverage, for example the extremities, junctional regions (groin, axilla, neck) or the face, based on combat wound distribution data, and whether coverage of particular regions will be evaluated or scored. Please also confirm whether the 15% total body surface area may be met by coverage of a single anatomical region or must be distributed across multiple regions.Any anatomical region for a minimum of 15% total body surface area; can be distributed across multiple areas and can be achieved through multiple applications.
74Request for Project Proposal (RPP); Attachment H — Statement of Work TemplateRPP proposal preparation instructions (Volume I and Volume II content); Attachment H milestone tableCost information in technical volumesThe RPP instructs that no cost or pricing information be included in Volume I or Volume II, and states that failure to comply may result in rejection. Attachment H, which is submitted as part of Volume I, includes a milestone table with a payment amount column. Please confirm whether offerors should complete the payment column in Attachment H within Volume I, or leave it blank in Volume I and provide milestone payment amounts only in the cost volume.Per the RPP, Section 3.5, which states, "All budget information must be addressed ONLY in Volume III: Administrative and Cost/Price." No cost/price information shall submt in Volumes I or II. Attachment G1 and G2 contain a tab where the milestone cost/price is to be identified.
75Request for Project Proposal (RPP); Attachment G2 — Cost/Price WorkbookAgreement type and payment structureFirm-fixed-price structure for clinical objectivesThe cost/price workbook is structured on a firm-fixed-price, milestone-payment basis. Objective 2 includes clinical studies whose final size and design depend on Objective 1 results and on FDA feedback that will not be available at the time of proposal. Please confirm whether the Government intends to award the entire agreement on a firm-fixed-price basis, or whether it will consider an alternative structure for Objective 2, for example a fixed-price Objective 1 with Objective 2 priced as a separately negotiated option or milestone set following the Pre-IND meeting, or cost-type or not-to-exceed pricing for clinical study execution.Per the RPP Section 2.1 Award Type: The Government prefers a Firm Fixed Priced (FFP) type pOTA. However, a cost-plus fixed fee (CPFF) is acceptable.
76Request for Project Proposal (RPP)Proposal preparation instructions; Volume II page limitationPage limits and appendicesVolume II is limited to 20 pages and must address the Regulatory Strategy/Development Plan, the Commercialization Plan and the Project Management Plan. Please confirm whether offerors may include the complete deliverable-grade versions of these documents as appendices or attachments excluded from the page count, or whether all content to be evaluated must appear within the 20 pages. Please also confirm whether cover pages, tables of contents, acronym lists and the Integrated Master Schedule are excluded from the page count, and whether the Microsoft Project file for the Project Management Plan counts toward any page limit.Per the RPP, Volume II - Cover page is 2 page limit, table of contents is 1 page limit, Managment Approach, which includes Project Management Plan with Intergrated Master Schedule (include risk management plan, staffing plan, subcontractor management paln, and teaming agreements (if applicable), and work breakdown structure, and commercialization plan and Regulatory Plan, is a 20 page limit. If additional documents are available, pls include this as a statement with the proposal and if needs be, the gov't will request a copy.
77Request for Project Proposal (RPP)Written Cost Narrative; subcontractor and consultant commitmentsLetters of commitmentThe Written Cost Narrative requires signed letters of commitment from each proposed subcontractor and consultant identifying the name, service, timeframe and agreed price. Contract development and manufacturing organizations, preclinical laboratories and clinical research organizations commonly require a defined scope and several weeks to issue binding pricing. Please confirm whether a signed letter of intent accompanied by a budgetary quotation is acceptable at the time of proposal submission, with binding pricing to be provided during negotiations prior to award.This is acceptable, HOWEVER proposed cost/price from teaming partners shall be finalized prior to award.
78Request for Project Proposal (RPP)Written Cost Narrative; labor ratesUnfilled labor positionsThe Written Cost Narrative requires labor rates by Government fiscal year with employee names. Please confirm how offerors should propose positions that will be filled after award, for example by labor category with a "to be hired" designation, a stated qualification requirement and a rate supported by published salary survey data, and whether such positions will be evaluated as fully responsive.If proposed labor positions are "unknown" at time of proposal, pls indicated "to be hired" and the hourly rate proposed. Per the RPP, Section 3.5, "The narrative must indicate how the proposed cost/price is realistic, reasonable, and complete. Cost/price support documentation is required for the Government to properly perform a cost/price analysis of the proposal."

This is the start of the file's text. The full file is on GovTribe.

File details come from the government source that posted it. Updated .